RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNXT RenovoRx Inc

Closed 12-18 16:00:00 EST

0.9000

+0.0300

+3.45%

盘后0.9015

+0.0015+0.17%

19:36 EST

High0.9211	Low0.8650	Vol91.81K
Open0.8900	D1 Closing0.8700	Amplitude6.45%
Mkt Cap32.98M	Tradable Cap27.08M	Total Shares36.65M
T/O82.48K	T/O Rate0.31%	Tradable Shares30.09M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RNXT","market":"US","secType":"STK","nameCN":"RenovoRx Inc","latestPrice":0.9,"timestamp":1766091600000,"preClose":0.87,"halted":0,"volume":91813,"hourTrading":{"tag":"盘后","latestPrice":0.9015,"preClose":0.9,"latestTime":"19:36 EST","volume":636,"amount":576.52,"timestamp":1766104616234},"delay":0,"floatShares":30093240,"shares":36649916,"eps":-0.34226,"marketStatus":"Closed","change":0.03,"latestTime":"12-18 16:00:00 EST","open":0.89,"high":0.9211,"low":0.865,"amount":82484.064696,"amplitude":0.064483,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.34226,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"listingDate":1629950400000,"exchange":"NASDAQ","adjPreClose":0.87,"preHourTrading":{"tag":"盘前","latestPrice":0.8644,"preClose":0.87,"latestTime":"09:14 EST","volume":142,"amount":120.9581986,"timestamp":1766067294271},"postHourTrading":{"tag":"盘后","latestPrice":0.9015,"preClose":0.9,"latestTime":"19:36 EST","volume":636,"amount":576.52,"timestamp":1766104616234},"volumeRatio":0.438223},"requestUrl":"/m/hq/s/RNXT/tweets","defaultTab":"tweets","newsList":[{"id":"2592928879","title":"RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592928879","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592928879?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972855,"startTime":"0","endTime":"0","summary":"Ramtin Agah, Chief Medical Officer and director of RenovoRx Inc., has reported the acquisition of common shares of RenovoRx Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL9j0m1r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNXT","BK4539"],"gpt_icon":0},{"id":"2590951950","title":"RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590951950","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590951950?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:30","pubTimestamp":1765459800,"startTime":"0","endTime":"0","summary":"The Accepted Abstract Provides Supportive Evidence for the TAMP Therapy Platform’s Novel, Localized Approach to Targeted Chemotherapeutic Delivery via Additional Pharmacokinetic and Pharmacodynamic Da","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203909/0/en/RenovoRx-Announces-Acceptance-of-Clinical-Data-Abstract-at-the-ASCO-Gastrointestinal-Cancers-Symposium-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","BK4539","IAG","RNXT","BK4139"],"gpt_icon":0},{"id":"2589337720","title":"RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337720","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589337720?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:01","pubTimestamp":1765195262,"startTime":"0","endTime":"0","summary":"Ramtin Agah, Chief Medical Officer and Director of RenovoRx Inc., has reported the acquisition of common shares of RenovoRx Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL1Ssp0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","RNXT"],"gpt_icon":0},{"id":"2588778629","title":"RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778629","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778629?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:30","pubTimestamp":1764595800,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., Dec.  01, 2025  (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT)(“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196997/0/en/RenovoRx-CEO-Shaun-Bagai-to-Present-at-iAccess-Alpha-Virtual-Best-Ideas-Winter-Investment-Conference-2025-on-December-9th.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","IAG","BK4017","BK4139","BK4539"],"gpt_icon":0},{"id":"2586108084","title":"RenovoRx CMO Makes Bold Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2586108084","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586108084?lang=en_us&edition=fundamental","pubTime":"2025-11-25 10:11","pubTimestamp":1764036665,"startTime":"0","endTime":"0","summary":"New insider activity at RenovoRx ( ($RNXT) ) has taken place on November 24, 2025. RenovoRx’s Chief Medical Officer, Ramtin Agah, has made a signif...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/renovorx-cmo-makes-bold-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/renovorx-cmo-makes-bold-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNXT","BK4539"],"gpt_icon":0},{"id":"2586741514","title":"RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586741514","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586741514?lang=en_us&edition=fundamental","pubTime":"2025-11-25 07:00","pubTimestamp":1764025239,"startTime":"0","endTime":"0","summary":"Ramtin Agah, Chief Medical Officer and Director of RenovoRx Inc., reported the acquisition of common shares of RenovoRx Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL3zSSv7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","RNXT"],"gpt_icon":0},{"id":"2584443449","title":"RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th","url":"https://stock-news.laohu8.com/highlight/detail?id=2584443449","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584443449?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:30","pubTimestamp":1763559000,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., Nov.  19, 2025  (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT)(“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3190927/0/en/RenovoRx-CEO-Shaun-Bagai-to-Present-at-the-Alliance-Global-Partners-Emerging-AgBiotech-Bio-Solutions-Virtual-Showcase-on-November-20th.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4017","BK4539","RNXT","IAG"],"gpt_icon":0},{"id":"2584950314","title":"RenovoRx Showcases Cancer Therapy Advances and RenovoCath Commercialization in New Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2584950314","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584950314?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:38","pubTimestamp":1763491104,"startTime":"0","endTime":"0","summary":"RenovoRx Inc. has provided an update highlighting the commercialization of its FDA-cleared RenovoCath device, reporting approximately $900,000 in revenue year-to-date through the third quarter of 2025. The company expanded its customer base from five to fourteen approved cancer center customers, with quotes delivered to an additional ten centers. RenovoRx estimates a potential peak annual U.S. revenue opportunity of approximately $400 million for RenovoCath as a stand-alone device and notes the potential to expand its total addressable market over time. The company is also advancing combination therapies utilizing its proprietary Trans-Arterial Micro-Perfusion  platform. Its lead device/drug combination candidate, RenovoCath plus Gemcitabine, has received FDA Orphan Drug Designation for pancreatic and bile duct cancers. The ongoing pivotal Phase III TIGeR-PaC study for locally advanced pancreatic cancer observed increased overall and progression-free survival, with a 65% reduction in s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDLddqzv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNXT","BK4539"],"gpt_icon":0},{"id":"2584931943","title":"Strategic Expansion and Promising Clinical Results Justify Buy Rating for RenovoRx","url":"https://stock-news.laohu8.com/highlight/detail?id=2584931943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584931943?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:35","pubTimestamp":1763465745,"startTime":"0","endTime":"0","summary":"RenovoRx, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright reiterat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-expansion-and-promising-clinical-results-justify-buy-rating-for-renovorx-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-expansion-and-promising-clinical-results-justify-buy-rating-for-renovorx-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT"],"gpt_icon":0},{"id":"2583655013","title":"RenovoRx’s Innovative Cancer Treatment and Promising Phase 3 Study Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2583655013","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583655013?lang=en_us&edition=fundamental","pubTime":"2025-11-16 00:25","pubTimestamp":1763223936,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy of Maxim Group maintained a Buy rating on RenovoRx, retaining the price target of $4.00. Jason McCarthy has given his Buy ra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/renovorxs-innovative-cancer-treatment-and-promising-phase-3-study-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/renovorxs-innovative-cancer-treatment-and-promising-phase-3-study-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT"],"gpt_icon":0},{"id":"2583544633","title":"RenovoRx Earnings Call: Positive Momentum and Strategic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2583544633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583544633?lang=en_us&edition=fundamental","pubTime":"2025-11-15 08:34","pubTimestamp":1763166852,"startTime":"0","endTime":"0","summary":"Renovorx, Inc. (($RNXT)) has held its Q3 earnings call. Read on for the main highlights of the call. RenovoRx’s recent earnings call conveyed a pos...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/renovorx-earnings-call-positive-momentum-and-strategic-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/renovorx-earnings-call-positive-momentum-and-strategic-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT"],"gpt_icon":0},{"id":"2583687043","title":"RenovoRx Enters Capital on Demand Sales Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2583687043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583687043?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:29","pubTimestamp":1763159370,"startTime":"0","endTime":"0","summary":"RenovoRx ( ($RNXT) ) has provided an update. On November 14, 2025, RenovoRx, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTradi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/renovorx-enters-capital-on-demand-sales-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/renovorx-enters-capital-on-demand-sales-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT"],"gpt_icon":0},{"id":"2583868407","title":"BRIEF-RenovoRx May Offer Securities For Up To $50 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583868407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583868407?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:38","pubTimestamp":1763156317,"startTime":"0","endTime":"0","summary":"BRIEF-RenovoRx May Offer Securities For Up To $50 Million - SEC FilingNov 14 (Reuters) - RenovoRx Inc RNXT.O:RENOVORX INC - MAY OFFER SECURITIES FOR UP TO $50 MILLION - SEC FILINGSource text: [ID:n0001493152-25-023525]Further company coverage: RNXT.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4539","BK4139"],"gpt_icon":0},{"id":"2583684046","title":"RenovoRx Inc - May Offer Securities for up to $50 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583684046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583684046?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:38","pubTimestamp":1763156292,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNXT","BK4539","BK4139"],"gpt_icon":0},{"id":"2583686013","title":"Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Forte Biosciences (FBRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583686013","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583686013?lang=en_us&edition=fundamental","pubTime":"2025-11-15 03:30","pubTimestamp":1763148622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on RenovoRx (RNXT – Research Report) and Forte Bioscien...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-renovorx-rnxt-and-forte-biosciences-fbrx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-renovorx-rnxt-and-forte-biosciences-fbrx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","FBRX","BK4588","HCSG","LU0128526141.USD","RNXT","BK4539","XBI","BK4585","LU0029874061.USD","BK4139","XLV","BK4581","LABU"],"gpt_icon":0},{"id":"2583168987","title":"RenovoRx price target lowered to $3 from $3.50 at Alliance Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2583168987","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583168987?lang=en_us&edition=fundamental","pubTime":"2025-11-15 03:20","pubTimestamp":1763148032,"startTime":"0","endTime":"0","summary":"Alliance Global lowered the firm’s price target on RenovoRx (RNXT) to $3 from $3.50 and keeps a Buy rating on the shares after the company reported...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/renovorx-price-target-lowered-to-3-from-3-50-at-alliance-global-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/renovorx-price-target-lowered-to-3-from-3-50-at-alliance-global-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT"],"gpt_icon":0},{"id":"2583015517","title":"RenovoRx Expands Reach with RenovoCath Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2583015517","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583015517?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:54","pubTimestamp":1763070890,"startTime":"0","endTime":"0","summary":"RenovoRx ( ($RNXT) ) has issued an announcement. RenovoRx reported its third-quarter 2025 financial results, highlighting approximately $900,000 in...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/renovorx-expands-reach-with-renovocath-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/renovorx-expands-reach-with-renovocath-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT","BK4139","BK4539"],"gpt_icon":0},{"id":"2583120795","title":"Cancer drug developer RenovoRx's Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2583120795","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583120795?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:38","pubTimestamp":1763069880,"startTime":"0","endTime":"0","summary":"Cancer drug developer RenovoRx's Q3 net loss widensOverviewRenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progressNet loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP18R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4539","BK4139"],"gpt_icon":0},{"id":"2583751418","title":"RenovoRx Q3 EPS $(0.08), Inline, Sales $266.000K Miss $405.333K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583751418","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583751418?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:11","pubTimestamp":1763068290,"startTime":"0","endTime":"0","summary":"RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period last year.  The company","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48850358/renovorx-q3-eps-0-08-inline-sales-266-000k-miss-405-333k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"gpt_icon":0},{"id":"2583848514","title":"BRIEF-RenovoRx Q3 Net Income USD -2.912 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583848514","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583848514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067950,"startTime":"0","endTime":"0","summary":"BRIEF-RenovoRx Q3 Net Income USD -2.912 Million\n\n\nNov 13 (Reuters) - RenovoRx Q3 operating expenses USD 3.413 million.\n\nQ3 basic EPS USD -0.08","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX8457A8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4539","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.renovorx.com","stockEarnings":[{"period":"1week","weight":-0.1094},{"period":"1month","weight":0.082},{"period":"3month","weight":-0.3095},{"period":"6month","weight":-0.3696},{"period":"1year","weight":-0.304},{"period":"ytd","weight":-0.3256}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.121404},{"month":2,"riseRate":0.75,"avgChangeRate":0.165499},{"month":3,"riseRate":0,"avgChangeRate":-0.152336},{"month":4,"riseRate":0,"avgChangeRate":-0.164804},{"month":5,"riseRate":0.5,"avgChangeRate":0.046228},{"month":6,"riseRate":0.5,"avgChangeRate":0.03467},{"month":7,"riseRate":0.25,"avgChangeRate":-0.034228},{"month":8,"riseRate":0.25,"avgChangeRate":-0.119414},{"month":9,"riseRate":0.4,"avgChangeRate":-0.050074},{"month":10,"riseRate":0,"avgChangeRate":-0.120676},{"month":11,"riseRate":0.6,"avgChangeRate":0.028303},{"month":12,"riseRate":0.6,"avgChangeRate":0.48619}],"exchange":"NASDAQ","name":"RenovoRx Inc","nameEN":"RenovoRx Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RenovoRx Inc,RNXT,RenovoRx Inc股票,RenovoRx Inc股票老虎,RenovoRx Inc股票老虎国际,RenovoRx Inc行情,RenovoRx Inc股票行情,RenovoRx Inc股价,RenovoRx Inc股市,RenovoRx Inc股票价格,RenovoRx Inc股票交易,RenovoRx Inc股票购买,RenovoRx Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction